Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Gap Inc V.GAP


Primary Symbol: GAP

The Gap, Inc. is a specialty apparel company in America. The Company offers apparel, accessories and personal care products for women, men and children. Its Old Navy, Gap, Banana Republic, and Athleta brands offer clothing, accessories and lifestyle products for men, women and children. It is an omni-channel retailer, with sales to customers both in stores and online, through Company-operated and franchise stores, websites, and third-party arrangements. Its omni-channel services, including buying online pick-up in store, order-in-store, find-in-store, and ship-from-store, as well as enhanced mobile-enabled experiences, are tailored across its collection of brands. Gap includes adult apparel and accessories, GapKids, babyGap, Gap Maternity, GapBody, and GapFit collections. Banana Republic is a premium lifestyle retailer celebrating exploration and self-expression through timeless quality, versatile fabrics, and exceptionally made womenswear, menswear, and home designs.


NYSE:GAP - Post by User

Bullboard Posts
Post by funkyfernyon Sep 14, 2009 1:28pm
337 Views
Post# 16303818

Look at the exposure of this compound..

Look at the exposure of this compound..$0$0$0Sounds familiar?  Stem cell research....targetted therapies actually working...cancer and diabietes having close ties in terms of efficacy with this compound....could GAP-107B have the same effectiveness on diabetes as it does on cancer?  Thoughts?$0$0Sounds like GAP-107B8 will blow this right out of the water!$0$0$0$0$0$0$0$0Anti-diabetes drug effective against cancer: study$0$0Updated Mon. Sep. 14 2009 12:25 PM ET$0$0CTV.ca News Staff$0$0A new study is providing even more evidence that a widely-used anti-diabetes drug may also be effective in fighting breast cancer.$0$0The new study from Harvard Medical School found that combining metformin, sold as Glucophage, with the chemotherapy drug doxorubicin, reduced breast cancer tumours faster than doxorubicin alone, when tested on mice.$0$0What's more, the drug combo also prolonged remission in the mice longer than chemotherapy alone.$0$0The researchers, writing in the journal Cancer Research, say the metformin combo seems to work by targeting the cancer's stem cells and may improve breast cancer outcomes in people.$0$0Evidence is growing that part of the reason why many cancers recur is that current treatments do not target a cancer's stem cells, which can resist chemotherapy and regenerate the various cell types in a tumour. So some researchers have been investigating therapies that selectively target cancer stem cells.$0$0Now, researchers think they've found one that shows promise.$0$0"We have found a compound selective for cancer stem cells," said senior author Kevin Struhl, a professor of biological chemistry and molecular pharmacology at Harvard Medical School. "What's different is that ours is a first-line diabetes drug."$0$0Metformin is a medication widely used to treat type 2 diabetes and is especially effective in obese diabetics who overproduce insulin. It works by preventing the liver from breaking down starch into sugar while also stimulating uptake of sugar by the body's muscles, causing blood sugar and insulin levels to fall.$0$0But the drug has also been found to reduce cancer risk. A number of studies have found that diabetic patients who take metformin have a significantly lower cancer rate, with those taking the highest doses for the longest period of time having the lowest rates.$0$0In this study, the drug seemed to work independently of its ability to improve insulin sensitivity and lower blood sugar levels. Instead, when combined with doxorubicin, metformin appeared to kill human cancer stem cells and non-stem cancer cells.$0$0For the study, researchers introduced human breast cancer stem cells into mice. Among those mice that were pretreated with metformin, the cancer cells failed to form tumours.$0$0In other mice not pre-treated and whose tumours were allowed to take hold for 10 days, the metformin-doxorubicin combination reduced tumour mass more quickly and prevented relapse for longer than doxorubicin alone.$0$0In the two months between the end of treatment and the end of the experiment, tumours regrew in the mice treated with chemotherapy alone, but not in those who received both drugs.$0$0By itself, metformin was ineffective in treating tumours.$0$0It remains to be seen whether the results from Struhl's study will be transferrable to humans with breast cancer. But Dr. Jennifer Ligibel, a medical oncologist and a Harvard Medical School instructor in medicine is about to begin a large-scale phase II trial on humans, with the National Cancer Institute of Canada's Clinical Trials Group.$0$0That trial will compare the effect of adding metformin or a placebo to chemotherapy following surgery for early breast cancer. The study will include both patients with type 2 diabets and high insulin levels, and non-diabetic women.$0$0"This is an exciting study," Ligibel said in response to this latest metformin study on mice.$0$0"There is a lot of interest in studying metformin in breast cancer, but so far we do not have direct evidence that metformin will improve outcomes in patients... That's what this trial is for."$0$0$0$0LONG AND STRONG!!$0$0$0
Bullboard Posts